jak-2-in-4

JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.

JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations. This compound exhibits proapoptotic properties, inhibits histone deacetylation, and impedes STAT3 phosphorylation, demonstrating notable antiproliferative activity against various hematological malignancies and solid tumors [1].

MEDI-2045 is a humanized monoclonal antibody targeting the interleukin-4 receptor alpha subunit (IL-4Ra/CD124). IL-4Ra is a pivotal receptor driving Type 2 inflammation, serving as an essential component of the shared receptor complexes for both IL-4 and IL-13. By specifically binding to IL-4Ra, this antibody dually blocks IL-4 and IL-13 signaling, thereby inhibiting the downstream JAK-STAT signaling pathway. This mechanism significantly attenuates inflammation involved in Th2 cell activation, B-cell class switching to IgE, and eosinophil recruitment, making it a critical tool for immunological research in asthma, atopic dermatitis, and other allergic diseases.